Denmark-based biopharmaceutical company Orphazyme closed its series A round of funding on the 7th of September, raising €14m ($19.2m). The round was funded by Novo Ventures, the corporate venturing unit of Denmark-based healthcare company Novo, and venture capital firms Aescap Ventures and Sunstone Capital. Novo A/S acts as the holding company for its parent corporation,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.